| Title |
An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer
|
|---|---|
| Published in |
Drugs, August 2018
|
| DOI | 10.1007/s40265-018-0972-9 |
| Pubmed ID | |
| Authors |
Marie Robert, Jean-Sébastien Frenel, Emmanuelle Bourbouloux, Dominique Berton Rigaud, Anne Patsouris, Paule Augereau, Carole Gourmelon, Mario Campone |
| Abstract |
Deregulated cell division, resulting in aberrant cell proliferation, is one of the key hallmarks of cancer. Cyclin-dependent kinases (CDKs) play a central role in cell cycle progression in cancer, and the clinical development of the CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib has changed clinical practice in the setting of endocrine-receptor positive breast cancer. Results of pivotal phase II and III trials investigating these CDK4/6 inhibitors in patients with endocrine receptor-positive, advanced breast cancer have demonstrated a significant improvement in progression-free survival, with a safe toxicity profile. No validated biomarkers of sensitivity or resistance exist at the moment. Future development of CDK4/6 inhibitors in breast cancer should focus on the identification of predictive biomarkers, the development of drug combinations to overcome resistance, and the application of CDK4/6 inhibitors to other breast cancer subtypes. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 17% |
| Unknown | 5 | 83% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 67% |
| Science communicators (journalists, bloggers, editors) | 2 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 14% |
| Student > Doctoral Student | 3 | 10% |
| Researcher | 3 | 10% |
| Student > Master | 2 | 7% |
| Professor | 1 | 3% |
| Other | 3 | 10% |
| Unknown | 13 | 45% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 21% |
| Biochemistry, Genetics and Molecular Biology | 3 | 10% |
| Medicine and Dentistry | 3 | 10% |
| Agricultural and Biological Sciences | 2 | 7% |
| Computer Science | 2 | 7% |
| Other | 1 | 3% |
| Unknown | 12 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 April 2019.
All research outputs
#7,517,664
of 23,102,082 outputs
Outputs from Drugs
#1,343
of 3,289 outputs
Outputs of similar age
#130,162
of 334,198 outputs
Outputs of similar age from Drugs
#21
of 31 outputs
Altmetric has tracked 23,102,082 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 3,289 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 334,198 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.